TrialJCO precision oncology2021

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III

Joel W Neal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.